

Important Contact Details

My name:

My emergency contact (name and phone number):

Doctor's name – who prescribed Venclyxto™:

Doctor's contact phone number:

<https://medicinesauthority.gov.mt/rmm>
MT-VNCLY-250001

Date approved: May 2025
abbvie



Important Safety Information for Healthcare Professionals about Venclyxto® and TLS

This patient is taking Venclyxto® for CLL which may cause Tumour Lysis Syndrome (TLS) in the first 5 weeks of treatment.

- Evaluate blood chemistries: potassium, uric acid, phosphorus, calcium and creatinine.
- Urgently correct blood chemistry abnormalities. **This can be fatal, if left untreated.**
- If you suspect TLS, contact prescribing doctor listed on this card immediately.

Please consult the Summary of Product Characteristics (SmPC) or contact AbbVie's local representative V.J. Salomone Pharma Ltd. at +356 99644126 for more information and if you need additional copies of the patient card.

Patient Card

Safety Information about Venclyxto® (venetoclax) for Patients with Chronic Lymphocytic Leukaemia (CLL)

Venclyxto is used to treat patients with CLL. This card contains information you need to know about Tumour Lysis Syndrome and Venclyxto®.

You can report side effects directly using the Medicines Authority ADR reporting form, which is available online at <http://www.medicinesauthority.gov.mt/adrportal>, and sent by post or email to:
Post: Pharmacovigilance Section at Post-Licensing Directorate, Medicines Authority, Sir Temi Żammit Buildings, Malta Life Sciences Park, San Gwann SGN 3000
E-mail: postlicensing.medicinesauthority@gov.mt
Alternatively, they may be reported by contacting AbbVie's local representative V.J. Salomone Pharma Ltd. at +35699644126.



- Keep this patient card with you all the time.
- Show it to any doctor involved in your medical care or if you go to the emergency department.
- Always take Venclyxto® exactly as your doctor has told you to.

What should I know about TLS?



During your treatment, you may develop high levels of certain body salts (such as potassium and uric acid) in the blood. This can lead to a condition called Tumour Lysis Syndrome (TLS) within the first 5 weeks of treatment.

TLS symptoms:

- fever or chills
- nausea or vomiting
- feeling confused
- feeling short of breath
- irregular heart beat
- dark or cloudy urine
- feeling unusually tired
- muscle pain or joint pain
- fits or seizures
- abdominal pain and bloating

What should I do if I get TLS symptoms?

If you experience any TLS symptoms during your treatment, you should:

-  **Call your doctor or seek medical attention immediately, and**
-  **Stop taking Venclyxto[®]**

Read the Patient Information Leaflet (PIL) for more information.

How can I reduce my risk of getting TLS?



Drink at least **1.5 to 2 litres of water daily**:

- starting from 2 days before your first dose, and
 - on the day of your first dose, and
 - every day during first 5 weeks of treatment.
- Drinking plenty of water will help to remove high levels of blood salts through your urine.



Attend your scheduled **blood test appointments**, as they will help your doctor identify TLS.



Before your treatment with Venclyxto[®], start another medicine that helps prevent the build-up of the blood salt (uric acid) in your body, as instructed by your doctor.